Author | Edward Chu, MD


Tumor Heterogeneity and Implications for Clinical Practice

September 15, 2014

The issue of tumor heterogeneity is real, and it is present on several different levels. Without question, the presence of tumor heterogeneity has important clinical implications, and at this time, it represents a significant challenge to the success of cancer therapy.

Personalized Medicine and Anti-EGFR Antibody Therapy in the Treatment of Metastatic Colorectal Cancer: KRAS and Beyond

February 15, 2014

It was originally hoped that the presence of mutations in KRAS and other related genes would provide an easy answer as to whether to administer anti-EGFR antibody therapy to a given metastatic colorectal cancer patient. However, in nature nothing is simple, and there are a number of issues that practicing clinicians should be made aware of.